Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Summary

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

Timeline

Start

2023-06-26

Primary completion

2023-11-27

Completion

2023-11-27

Publications

• Liu C, Ji Y, Wu X, Cerqueira B, Cade D, Du P, Yang Z. Evaluation of [89Zr]Zr-girentuximab PET imaging of clear cell renal cell carcinoma in chinese patients: a Phase 1 clinical study (ZIRDOSE-CP). EJNMMI Res. 2025 Dec 24;16(1):1. doi: 10.1186/s13550-025-01332-5.

Drugs

Indications